Tarso Adoni

Sao Paulo, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center.

Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center.

Journal: Arquivos de neuro-psiquiatria

Published: May 18, 2026

Alemtuzumab in Brazilian multiple sclerosis care: major gaps in mandatory monitoring over 24 months.

Alemtuzumab in Brazilian multiple sclerosis care: major gaps in mandatory monitoring over 24 months.

Journal: Multiple sclerosis and related disorders

Published: April 30, 2026

Estimated prevalence and distribution of causes of immune-mediated hypertrophic pachymeningitis in São Paulo, Brazil.

Estimated prevalence and distribution of causes of immune-mediated hypertrophic pachymeningitis in São Paulo, Brazil.

Journal: Clinical rheumatology

Published: April 30, 2026

Antineutrophil cytoplasmic antibody-associated pachymeningitis: a systematic review of clinical features, diagnosis and treatment outcomes.

Antineutrophil cytoplasmic antibody-associated pachymeningitis: a systematic review of clinical features, diagnosis and treatment outcomes.

Journal: Immunologic research

Published: February 23, 2026

Is serum neurofilament light chain accurate enough to guide multiple sclerosis care? Diagnostic performance and optimal cutoff in a systematic review and meta-analysis.

Is serum neurofilament light chain accurate enough to guide multiple sclerosis care? Diagnostic performance and optimal cutoff in a systematic review and meta-analysis.

Journal: Multiple sclerosis and related disorders

Published: February 23, 2026

To stop or not to stop: the clinical dilemma of long-term double-seronegative neuromyelitis optica therapy.

To stop or not to stop: the clinical dilemma of long-term double-seronegative neuromyelitis optica therapy.

Journal: Arquivos de neuro-psiquiatria

Published: February 04, 2026

Lymphopenia predicts infectious complications after alemtuzumab therapy in multiple sclerosis: Real-world experience from a Brazilian cohort.

Lymphopenia predicts infectious complications after alemtuzumab therapy in multiple sclerosis: Real-world experience from a Brazilian cohort.

Journal: Clinical neurology and neurosurgery

Published: January 31, 2026

Diagnosis and antibody status awareness in neuromyelitis optica spectrum disorder and MOG-associated disease: A cross-sectional study.

Diagnosis and antibody status awareness in neuromyelitis optica spectrum disorder and MOG-associated disease: A cross-sectional study.

Journal: Multiple sclerosis and related disorders

Published: December 11, 2025

2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children.

2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children.

Journal: Arquivos de neuro-psiquiatria

Published: November 10, 2025

Therapeutic plasma exchange for MOG antibody-associated disease attacks: a systematic review and meta-analysis.

Therapeutic plasma exchange for MOG antibody-associated disease attacks: a systematic review and meta-analysis.

Journal: Multiple sclerosis and related disorders

Published: September 05, 2025

Therapeutic plasma exchange for MOG antibody-associated disease attacks: a systematic review and meta-analysis.

Therapeutic plasma exchange for MOG antibody-associated disease attacks: a systematic review and meta-analysis.

Journal: Multiple sclerosis and related disorders

Published: September 05, 2025

Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs.

Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs.

Journal: Lancet regional health. Americas

Published: April 04, 2025

Showing 1-12 of 65

Last Updated: 09/26/2026